Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended – Release Subcutaneous Injection: A Case Report

Opioid use disorder (OUD) continues to be a major public health crisis, with the current epidemic being driven by synthetic opioids such as illicitly manufactured fentanyl. While medications exist to treat OUD, only sublingual and subdermal buprenorphine formulations are approved for patients aged 16 –17 years. Furthermore, almost all pediatric patients who are diagnosed with OUD do not receive medication as treatment. This case describes the innovative use of buprenorphine extended-release subcutaneous injection in a 17-year-old with OUD who has achieved early remission after four months of treatment.
Source: Journal of Adolescent Health - Category: Child Development Authors: Tags: Clinical observations Source Type: research